secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001213900-25-035785
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months
-------------------------------------------------------------------------------

- BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.
- BCG-Naïve: 76% CR at any time (16/21), 43% at 12 months (3/7) in Phase 2 ADVANCED-2 trial.
- No Grade 3+ treatment-related adverse events; most AEs were Grade 1, transient, and consistent with immunopotentiation.
- Company on track to present interim data from ~25 six-month evaluable BCG-Unresponsive patients by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/0001213900-25-035785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/ea0239689-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-035785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer